The Food and Drug Administration has decided that more evidence of serelaxin’s efficacy as a treatment for acute heart failure is needed before the drug can be approved in the United States, Novartis...
SAN FRANCISCO – Defibrillation testing at the time of implantable cardioverter defibrillator implantation is safe, but it does not improve clinical shock efficacy or prevent death, results from a...
SAN FRANCISCO – Patients with implantable pacemakers and defibrillators who engage in remote monitoring at more than 75% adherence rates have a 2.4-fold higher rate of survival than those who do not...
Treatment with canagliflozin was associated with significant weight loss as well as improvements in glycemic control, when compared with placebo in a 26-week, phase III study of nearly 600...
Current recommendations and labeling regarding the use of dabigatran will not change, based on the results of a large observational cohort study comparing the risks of the direct thrombin inhibitor...
Adding evolocumab to both moderate- and high-intensity statin therapy lowered low-density lipoprotein cholesterol even further in an international phase III clinical trial reported online May 13 in...
WASHINGTON – Treating acute venous thromboembolism with the fixed-dose oral factor Xa inhibitor apixaban significantly reduces subsequent all-cause hospitalizations, compared with conventional...
Physical inactivity in women aged 30 years and older has a greater impact on the risk of developing heart disease than any other major risk factor, according to an Australian study published today in...
The Food and Drug Administration has rejected the approval of the intravenous antiplatelet drug cangrelor, suggesting that the company provide more data, according to the drug’s manufacturer.
The...
CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease.
In a nationwide case-control study of prodigious proportions,...
